What is Exelixis?
Exelixis is a oncology biopharmaceuticals company serving enterprise, public-sector, commercial, consumer, or regulated-market customers.
- Category
- Oncology biopharmaceuticals
- Headquarters
- Alameda, CA
- Founded
- See official company history
- Employees
- See latest annual report and company filings
- Total funding
- Public company
- Status
- Public company; Nasdaq: EXEL
What is Exelixis?
Exelixis is a oncology biopharmaceuticals company headquartered in Alameda, CA. Its public-company profile is most useful for account planning when combined with current filings, investor materials, job posts, product launches, and partner announcements.
Exelixis is a oncology biopharmaceuticals company headquartered in Alameda, CA. Its public-company profile is most useful for account planning when combined with current filings, investor materials, job posts, product launches, and partner announcements.
For sellers, Exelixis should be mapped as a scaled public-company account rather than an early-stage company. The best timing signals are earnings commentary, capital spending, hiring clusters, product launches, acquisitions, facility investments, and leadership changes.
What does Exelixis offer?
Exelixis's profile centers on CABOMETYX, Cancer medicines, Oncology pipeline, Clinical collaborations.
- CABOMETYX· Oncology biopharmaceuticals
- Cancer medicines· Oncology biopharmaceuticals
- Oncology pipeline· Oncology biopharmaceuticals
- Clinical collaborations· Oncology biopharmaceuticals
- Targeted therapies· Oncology biopharmaceuticals
- Commercial oncology· Oncology biopharmaceuticals
How does Exelixis make money?
Exelixis makes money through commercial activity tied to oncology biopharmaceuticals.
Exelixis monetizes through the model common to oncology biopharmaceuticals: product sales, recurring services, subscriptions, contracts, distribution, transaction volume, underwriting, regulated utility revenue, or usage depending on the operating unit.
Sales angles should connect to measurable priorities such as margin, growth, uptime, compliance, retention, automation, risk reduction, data quality, customer experience, or field productivity.
Who leads Exelixis?
Exelixis's named executives should be verified on the official leadership or investor-relations page before outreach.
- Exelixis executive leadershipExecutive leadership teamCurrent as of June 2026Use the official leadership, governance, or investor-relations page for current named executives before outreach.
- Exelixis finance leadershipFinance / CFO organizationCurrent as of June 2026Often owns investor communication, procurement governance, capital allocation, and budget discipline.
- Exelixis operations or technology leadershipOperations, product, technology, security, or commercial leadershipCurrent as of June 2026Likely stakeholder group for software, infrastructure, data, workflow, and operating-improvement purchases.
How do you contact Exelixis's leadership?
Exelixis should be contacted through official investor, media, partner, support, or sales routes unless a named executive publishes a direct address.
contact via https://www.exelixis.com- Exelixis investor relationsInvestor relations / corporate contactcontact via https://www.exelixis.com
How is Exelixis funded?
Exelixis's current status is Public company; Nasdaq: EXEL.
Exelixis's capital profile is best understood through its current public-company status: Public company; Nasdaq: EXEL. For public companies, financing and budget signals are usually found in annual reports, quarterly results, debt disclosures, buybacks, acquisitions, capex plans, and management commentary rather than venture funding rounds.
Before outreach, verify the latest status on the company's investor-relations page and current exchange filings.
How did Exelixis get here?
Exelixis's history should be read through founding, scale-up, public-market ownership, and current product or market focus.
- FoundingExelixis is foundedThe company begins building in oncology biopharmaceuticals.
- Scale-upCommercial footprint expandsExelixis broadens its product, customer, distribution, or geographic reach.
- Public marketsPublic company; Nasdaq: EXELPublic-company ownership shapes reporting, procurement, and operating priorities.
- 2025Scaled operating profileThe company operates with specialized teams and repeatable buying centers.
- June 2026Current profile refreshedProfile generated from official domain, public-company status, and source references.
Who are Exelixis's competitors?
Exelixis competes with larger incumbents and focused specialists in oncology biopharmaceuticals.
- Thermo Fisher ScientificLife sciences tools, diagnostics, and services incumbent.
- DanaherLife sciences and diagnostics platform company.
- MedtronicGlobal medical technology competitor.
- PfizerLarge pharmaceutical company with global commercial reach.
- IQVIAHealthcare data and clinical research platform competitor.
Exelixis — frequently asked questions
